Enrollment exceeding expectations in DURAVYU™ Phase 3 wet AMD clinical trials with LUGANO over 50% enrolled and LUCIA recruiting ahead of ...

Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end ...

Q4 2024 Earnings Call Transcript March 3, 2025 Ocular Therapeutix, Inc. misses on earnings expectations. Reported EPS is ...

Praxis' epilepsy pipeline takes center stage after Ulixacaltamide's Phase 3 futility. Key trials for vormatrigine and ...

The Phase 3 ARTEMIS trial (NCT06856577) is designed to evaluate the safety and efficacy of Ixo-vec in a randomized (1:1), double-masked, sham-controlled, two-arm study. The US-based trial is intended ...

Intensifying oral diuretic therapy was linked to worse prognosis, but not everybody is sold on its use an endpoint.

In honor of Rare Disease Day on February 28, 2025, we will publish a series of posts throughout the month on As Prescribed ...

Rusfertide met all primary and secondary endpoints in a Phase 3 trial for polycythemia vera, with strong efficacy and safety ...

A clinical trial to test the effectiveness of a new, plant-based oral drug to treat type 2 diabetes has produced some ...

Clene will join APST Research to explore how CNM-Au8 affects NfL levels in ALS patients treated in expanded access programs.